Kiniksa Pharmaceuticals International plc (KNSA) has reported strong financial results for the first quarter of 2025 and has boosted its revenue outlook for the year.
The company's flagship product is Arcalyst, the first and only FDA-approved therapy for recurrent pericarditis, a painful and debilitating auto-inflammatory cardiovascular disease. The drug was licensed from Regeneron in 2017.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com